Onco Actu du 23 mars 2016

	4.10 Dép., diag. & prono. - Poumon
High-Risk Lung Cancer Patients May Not Need Annual Screenings [Duke Medicine] The researchers found that even former heavy smokers appear to have a reduced incidence of lung cancer if their initial LDCT screening is negative, suggesting that less frequent screening might be warranted.
	4.2 Dép., diag. & prono. - Génome
Complex diseases need complex solutions – including genomics [PHG Foundation] Since motivating health-related behaviour change is extraordinarily difficult in general, it is not really surprising that genomic information does not confer greater influencing power than other types of risk information.
Predictions for Precision Medicine get an evidence-based reality check   [HealthNewsReview] This all brings me back to hypothetical patient “John” from 2010. John would now be close to 30 years old. Unfortunately the sort of unambiguous genetic information about risks for common diseases anticipated in the 1990s has not emerged.
Knowledge of genetic risk doesn't prompt behavior changes [Reuters] “Inducing behavior change for diet and exercise and is extremely difficult, and these subjects were not offered any support,” Collins told Reuters Health by phone. “Even if they thought they should do something about it there was no assistance.”
	5. Traitements
Frequent MRI scans help to target bladder cancer [The Institute of Cancer Research] The researchers believe that this kind of approach – called MRI-guided adaptive radiotherapy (MRIGART) – will be a significant step forward in future radiotherapy treatment of patients with urinary bladder cancer.
	5.2.1 Pharma - Partenariats
J&J joins up with Genentech for a pair of atezo/Darzalex combo cancer studies [FierceBiotech] Genentech and Johnson & Johnson are joining hands on another checkpoint combo program, matching Darzalex (daratumumab) and the PD-L1 drug atezolizumab for an unidentified solid tumor as well as multiple myeloma, where Darzalex is already approved for use.
	5.4 Traitements - Economie
What GlaxoSmithKline CEO Andrew Witty Doesn't Get About Drug Pricing [Forbes] It is often correctly pointed out that nine out of ten experimental medicines that enter clinical trials fail. This fact is used to justify the high price of a new drug. But this, too, is irrelevant. Why should it be expected that payers and patients pay for the failures of an industry?
	6. Lutte contre les cancers
'Rapid autopsies' are a new frontier in cancer research [STAT] “There’s horrible poetry to the idea that your tumor lives longer than you do, but that’s what happens with this,” said Dr. Jody Hooper, a pathologist who runs the rapid autopsy program at Johns Hopkins Medicine. “Tissue has become the holy grail.”
Guideline Addresses Long-term Needs of Head and Neck Cancer Survivors [ACS] Fourth in series of cancer survivorship care guidelines.
Back to the Essence of Medical Treatment in Oncology [ESMO] The latest article to appear on ESMO Open highlights ESMO’s hope that the 2015 WHO Model List of Essential Medicines (EML) will empower oncologists and advocates to demand routine availability of the medicines considered essential to guarantee quality care of cancer patients.
	6.1 Observation
Male survivors of childhood cancer three times as likely to suffer infertility as women [The Telegraph] Male survivors of childhood cancer three times as likely to suffer infertility as women. Most girls who survive childhood cancer can still go on to become mothers, research found.
	6.3 Associations
From April we’re changing the way we communicate with supporters [Cancer Research UK] So from April, we’ve decided to give supporters the chance to ‘opt-in’ to future fundraising communications from us. This means that we’re going to start asking all new supporters to give us permission to contact them before we ask for any further support. And, if they don’t, they won’t receive a fundraising request.
	6.6 Publications
Set up a ‘self-retraction’ system for honest errors [Nature News & Comment] Notices should make obvious whether a withdrawal of research is the result of misconduct or a genuine mistake, says Daniele Fanelli.
	6.7.2 Applis
Apple's New CareKit Platform Allows Any User To Collect Medical Data [Huffington Post] “What became clear to us later is that the very same tools used to advance medical research can also be used to help people with their care,” said Jeff Williams, Apple’s chief operating officer.
	6.8 Communication
How Journalists Can Help Hold Scientists Accountable [Pacific Standard] Science reporters don't usually look at research funding, nor do they critically evaluate the quality of the studies that they cover. Often, they lack the time or technical knowledge to dig into stories. In other cases, they may just be worried about challenging expert authority.